A non-randomized dose-escalation Phase I trial of a protein-based immunotherapeutic for the treatment of breast cancer patients with HER2-overexpressing tumors
Overview of attention for article published in Breast Cancer Research and Treatment, March 2016
Altmetric Badge
About this Attention Score
-
Good Attention Score compared to outputs of the same age (67th percentile)
-
Good Attention Score compared to outputs of the same age and source (78th percentile)
Readers on
- mendeley
- 52 Mendeley